

- 2 -

IN THE CLAIMS

Please cancel Claim 26.

Please amend Claims 22, 24, and 27-33 as detailed below.

Please add new Claims 34-40 as detailed below.

1. (previously presented) A method for impairing movement of a cutaneous lymphocyte-associated antigen<sup>+</sup> (CLA<sup>+</sup>) memory T-cell within or to the skin of a mammal, said method comprising administering to said mammal an effective amount of an antibody against cutaneous-T-cell-attracting chemokine (CTACK), whereby administration of said antibody impairs movement of said cutaneous lymphocyte-associated antigen<sup>+</sup> memory T-cell within or to the skin of said mammal.

2. (canceled)

3. (previously presented) The method of Claim 1, wherein said movement is within said skin.

4. (previously presented) The method of Claim 1, wherein said antibody neutralizes cutaneous-T-cell-attracting chemokine.

5.-21. (withdrawn)

22. (currently amended) A method for treating a patient suffering from an inflammatory skin disorder comprising administering an effective amount of an antibody against cutaneous-T-cell-attracting chemokine.

23. (canceled)

24. (currently amended) The method of Claim 1, wherein said administering is local; ~~systemic, topical, subcutaneous, intradermal, or transdermal.~~

25. (previously presented) The method of Claim 1, wherein said cutaneous lymphocyte-associated antigen<sup>+</sup> memory T-cell moves into the dermis or epidermis of said skin.

26. (canceled)

27. (currently amended) The method of Claim 22, wherein said inflammatory skin disorder is allergic-contact dermatitis.

28. (currently amended) The method of Claim 22, wherein said inflammatory skin disorder is psoriasis.

29. (currently amended) The method of Claim 22, wherein said inflammatory skin disorder is wound healing,

- 3 -

30. (currently amended) The method of Claim 22, wherein said inflammatory skin disorder is cancer.
31. (currently amended) The method of Claim 22, wherein said inflammatory skin disorder is carcinoma.
32. (currently amended) The method of Claim 22, wherein said inflammatory skin disorder is infection.
33. (currently amended) The method of Claim 32, wherein said infection is microbial, ~~viral,~~  
~~or parasitic.~~
34. (new) The method of Claim 32, wherein said infection is viral.
35. (new) The method of Claim 32, wherein said infection is parasitic.
36. (new) The method of Claim 1, wherein said administering is systemic.
37. (new) The method of Claim 1, wherein said administering is topical.
38. (new) The method of Claim 1, wherein said administering is subcutaneous.
39. (new) The method of Claim 1, wherein said administering is intradermal.
40. (new) The method of Claim 1, wherein said administering is transdermal.